GHDX did an ASR today, for 30 mioUS$. Anybody out there who has an idea as to why - other than just pushing the EPS up short-term for the year end closing? Anybody who understands the instrument well enough to explain the strategic value of it in this particular case? At this level of intervention, this is not about taking GHDX private. What is it about? Just the EPS?
until you understand that this represents aprx 6% of the float.,or 3% of total shares and that certain parties will soon approach owning a majority of the company.Sure it could be sold and going private may not happpen.GHDX is a rare bird indeed.Take note that the SP was pushed to near the years low after being up 25% most of the rest of the year to facilitate not only this ASR but a large purchase by insiders in recent trades.
The buying last month was the Baker Brothers but this move has yielded no 5% SEC docs.I have a different take.The cap gains tax was paid for with this push down,.You can see it all the big holdings of the #$%$.Next year will be a min 50% gain if the co isnt sold or gone private
Terry - take a look in the Oregonian online and review an article about Oregon Health Sciences University (OHSU) and their genomic tests for cancer. My concern is that the field of genomic testing is getting crowded. Will GHDX need to lower prices to stay competitive?
Well, imho, what we should hope for is a better performance of management when they present YE results than the apalling stuttering at the occasion of Q3/12. And we should hope for better numbers to report on, too.